Search

Your search keyword '"Nagarajan, Arun"' showing total 137 results

Search Constraints

Start Over You searched for: Author "Nagarajan, Arun" Remove constraint Author: "Nagarajan, Arun"
137 results on '"Nagarajan, Arun"'

Search Results

2. Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

11. Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery.

12. Mechanically Tunable Slippery Behavior on Soft Poly(dimethylsiloxane) (PDMS) Based Anisotropic Wrinkles Infused with Lubricating Fluid

13. Enhanced Slippery Behavior and Stability of Lubricating Fluid Infused Nanostructured Surfaces

14. Investigation of slippery behaviour of lubricating fluid coated smooth hydrophilic surfaces

15. Electrowetting on dielectrics on lubricating fluid based slippery surfaces with negligible hysteresis

20. Data from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

21. Table S1, Table S2 from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

22. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

23. Liver Venous Deprivation for Rapid Liver Hypertrophy Before Major Hepatectomy: A Case Report

31. Further structural characterization of ovine forestomach matrix and multi-layered extracellular matrix composites for soft tissue repair

34. Number of nonsynonymous genomic variants may correlate with prognosis in advanced pancreatic cancer.

37. Further structural characterization of ovine forestomach matrix and multi-layered extracellular matrix composites for soft tissue repair.

38. E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

40. Total Neoadjuvant Treatment for Rectal Cancer: Preliminary Experience

41. A randomized phase II study of ipilimumab at 3 (ipi3) or 10 mg/kg (ipi10) alone or in combination with high dose interferon-alfa (HDI) in advanced melanoma (E3611).

Catalog

Books, media, physical & digital resources